Dual chamber prefilled syringes are being widely utilized for storing biological substances or active pharmaceutical components that cannot be stable for extended duration.
These syringes enable avoiding drug loss by maintaining sterility of drugs prior to injection.
Advancement in technology has resulted into improved arrangement of liquid components in syringes and injectors, attracting more patients toward opting for these safe and efficient syringes.
Lyophilized drugs have witnessed a robust penetration across the globe in the recent past. These drugs account for a major share of the all reconstitution-requiring injectable/infusible.
As a large number of injectable/infusible drugs have been developed for self-administration, special challenges are incurred for the drug developers.
However, dual chamber prefilled syringes, which are particularly designed for simplifying reconstitution devoid of patient handling of diluent or drug, have become the mainstay option for delivering these drugs, meanwhile curtailing challenges faced by developers.
With lyophilized drugs witnessing proliferated penetration, demand for dual chamber prefilled syringes will gain a significant upsurge in the foreseeable future.
A CAGR of 8.7% has been projected for the global dual chamber prefilled syringes market during the forecast period, 2017 to 2026, according to a new study of Fact.MR.
Roughly US$ 3,300 Mn worth of dual chamber prefilled syringes are likely to be sold across the globe by 2026-end.
North America to Remain Most Remunerative for Dual Chamber Prefilled Syringes Market
North America will continue to be the most remunerative market for dual chamber prefilled syringes.
Dominance of North America in the market can be highly attributed to growing prevalence of chronic diseases in the region coupled with high penetration of biologics and biosimilars.
Geographical expansion of North America-based market players, high demand for self-injection devices and growing geriatric population are some other factors driving growth of the market in North America.
Conventional prefilled syringes are expected to remain sought-after among products in the global dual chamber prefilled syringes market.
This can be attributed to factors such as relatively lower cost along with robust adoption of self-administered drugs.
Safety prefilled syringes are expected to record a comparatively faster sales expansion through 2026, mainly driven by growing focus of manufacturers in introducing technologically advanced and safe & efficient drug delivering prefilled syringes for minimizing risk to patients.
Glass to Remain Preferred Product Material for Dual Chamber Prefilled Syringes
Glass will remain preferred product material for dual chamber prefilled syringes, mainly because of its non-reactive nature, and properties such as chemical and heat resistance.
However sales of glass prefilled syringes will witness a comparatively slower expansion than plastic prefilled syringes through 2026.
Although hospital pharmacies are estimated to account for the largest market share during the forecast period, sales of dual chamber prefilled syringes in online pharmacies are poised to record the highest CAGR through 2026.
With trend toward surging adoption of self-injection syringes, and development of technologically advanced dual chamber prefilled syringes, leading players in the market are concentrating on expansion of their product portfolio and the market reach.
In this highly competitive and rapidly evolving market, players are emphasizing on the essentiality of up-to-date information for monitoring their performance and making critical decisions regarding profitability & growth.
Some players in the market are also focusing on making improvements in design of dual chamber prefilled syringes for improving stability and safety of sensitive drugs.
Fact.MR’s report has listed key players augmenting the market expansion, which include
- Bespak Europe Ltd
- Catalent, Inc.
- Credence MedSystems Inc.
- Otsuka America Pharmaceutical Inc.
- Schott AG
- West Pharmaceutical Services Inc.
- Ypsomed Holding AG
- Gerresheimer AG
- Vetter Pharma-Fertigung GmbH & Co. KG
- Nipro Corporation
- Boehringer Ingelheim GmbH
- Amgen Inc.
- Pfizer Inc
Avail customized purchase options for your needs
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.